"id","uuid:ID","label","instanceType","name","rationale","description"
"StudyDesign_1","0f5805d0-4f4a-4440-8cdc-8580e8a541ef","","StudyDesign","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study"
